Abeona Therapeutics INC.: insider trades · United States · SEC (Form 4)

About Abeona Therapeutics INC.

Abeona Therapeutics Inc. (ABEO) is a U.S.-based commercial-stage biopharmaceutical company listed on the NASDAQ in the United States, focused on cell and gene therapies for serious diseases with high unmet medical need. The company is headquartered in Cleveland, Ohio, and operates an integrated cGMP cell and gene therapy manufacturing facility there, which supports both development and commercial supply. Abeona’s roots date back to 1974, when it was incorporated as Chemex Corporation; it later changed its name to Abeona Therapeutics Inc. in 2015 as it repositioned toward rare disease and advanced-therapy development. ([abeonatherapeutics.com](https://www.abeonatherapeutics.com/?utm_source=openai)) Abeona’s most important current asset is ZEVASKYN® (prademagene zamikeracel), a cell-based gene therapy approved by the U.S. FDA in April 2025 for the treatment of wounds in adult and pediatric patients with recessive dystrophic epidermolysis bullosa (RDEB). The company describes ZEVASKYN as the first and only autologous cell-based gene therapy of its kind in the U.S. market, giving Abeona a first-mover position in an ultra-specialized rare-disease category. Commercial execution depends on a qualified-treatment-center network in the United States, which is central to referral flow, biopsy logistics, and therapy delivery. ([investors.abeonatherapeutics.com](https://investors.abeonatherapeutics.com/press-releases/detail/303/u-s-fda-approves-zevaskyn-prademagene-zamikeracel?utm_source=openai)) Beyond ZEVASKYN, Abeona continues to invest in a pipeline aimed at extending its platform into oncology and other high-value areas. Its lead development asset is ABO-701, a PSMA-targeted synthetic immune receptor T-cell therapy being developed for advanced prostate cancer. The company also highlights SIR technology and viral-vector capabilities as part of its broader research platform, with the strategic aim of addressing some of the limitations seen in conventional CAR-T approaches in solid tumors. While these programs remain earlier-stage, they illustrate that Abeona is not positioning itself as a single-product company. ([abeonatherapeutics.com](https://www.abeonatherapeutics.com/pipeline-and-science/?utm_source=openai)) From a competitive standpoint, Abeona operates in a niche where scientific differentiation, regulatory status, and manufacturing control matter more than scale alone. Its potential edge comes from combining an approved therapy, in-house production capacity, and an expanding treatment-center footprint. The key risks remain execution-heavy: scaling commercial uptake of ZEVASKYN, maintaining manufacturing quality and throughput, and funding ongoing pipeline development. Recent 2026 company updates emphasize building commercial momentum, expanding treatment activity, and advancing the pipeline, underscoring a company that has moved beyond pure R&D but is still in the early phases of scaling a new rare-disease franchise. ([nasdaq.com](https://www.nasdaq.com/press-release/abeona-therapeuticsr-reports-full-year-2025-financial-results-and-corporate-updates?utm_source=openai))